Drug Type Multi-specific antibody |
Synonyms RBT 101, RBT101 |
Target |
Action agonists |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | Canada | 01 Nov 2025 | |
| Hematologic Neoplasms | Preclinical | Canada | 01 Nov 2025 | |
| Melanoma | Preclinical | Canada | 01 Nov 2025 |






